Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 1 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Imvela Corp. currently manages 2 pending office actions. These matters are situated in the Biotechnology & Pharmaceuticals technology area. Both actions are assigned to 1 distinct examiner and are located within 1 distinct art unit. Lauren K Van Buren is the busiest examiner for the company, currently handling 2 pending actions.
This concentration means that Lauren K Van Buren is responsible for all of the company's current prosecution in the Biotechnology & Pharmaceuticals area. The use of 1 distinct art unit indicates a very specific technical focus for these 2 pending office actions. Practitioners should focus their efforts on the specific requirements and past decisions of Lauren K Van Buren. Because both of the 2 pending office actions are handled by the same individual, the company can expect a consistent examination style across its current portfolio. However, this also means that the company's success in the Biotechnology & Pharmaceuticals sector is currently dependent on a single examiner. The lack of distribution across multiple art units or examiners suggests a highly specialized and centralized intellectual property strategy at this time.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VAN BUREN, LAUREN K | 2 | 39.8% | +58.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19028696 | COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING AND PREVENTING HALITOSIS | VAN BUREN, LAUREN K | 73d overdue |
| 18790185 | COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING AND PREVENTING HALITOSIS | VAN BUREN, LAUREN K | 15d |
| Art Unit | Apps |
|---|---|
| 1638 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19028696 | COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING AND PREVENTING HALITOSIS | VAN BUREN, LAUREN K | 1638 | §103 | Final Rejection | 73d overdue | Pending | Jan 17, 2025 |
| 18790185 | COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING AND PREVENTING HALITOSIS | VAN BUREN, LAUREN K | 1638 | §103 | Non-Final OA | 15d | Pending | Jul 31, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial